Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 3:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 553 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vein Thrombosis Clear all
Completed Early Phase 1 Interventional

Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose

NCT02704052
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolus, Venous Thromboembolism
Interventions
Real time enoxaparin dose adjustment, Standard enoxaparin dose
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 4, 2026, 3:16 AM EDT
Completed Phase 3 Interventional Results available

The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome

NCT00143598
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Knee-length, graduated elastic compression stocking, Knee-length, placebo stocking
Device
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Other
Eligibility
18 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
3
States / cities
Detroit, Michigan • Durham, North Carolina • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 4, 2026, 3:16 AM EDT
Completed Phase 1 Interventional

Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion

NCT01028248
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Ranibizumab (Lucentis)
Drug
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Bakersfield, California • Santa Barbara, California • Santa Maria, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Oct 4, 2026, 3:16 AM EDT
Not yet recruiting Phase 3 Interventional

Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).

NCT06628778
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
Enoxaparin
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2035
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 4, 2026, 3:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema

NCT00403039
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Ranibizumab (Lucentis )
Drug
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Other
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 4, 2026, 3:16 AM EDT
Completed Not applicable Interventional Results available

A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter System

NCT01305564
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Denali inferior vena cava filter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hartford, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Oct 4, 2026, 3:16 AM EDT
Completed Phase 2 Interventional

Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism

NCT04041843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban
Drug
Lead sponsor
New York Medical College
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 4, 2026, 3:16 AM EDT
Completed Phase 3 Interventional

Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

NCT00135876
View directory record Official record
Conditions
Venous Thromboembolism, Brain Tumors
Interventions
dalteparin
Drug
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Evanston, Illinois • Detroit, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2007 · Synced Oct 4, 2026, 3:16 AM EDT
Completed Phase 4 Interventional Results available

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

NCT02464969
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban, Standard of Care
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
0 Days to 17 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
84
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 4, 2026, 3:16 AM EDT
Active, not recruiting Phase 4 Interventional

Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital

NCT07250763
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Atrial Fibrillation, Acute Cardiac Syndrome, Mechanical Heart Valve Recipients
Interventions
Initial Heparin Dose Modification
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 4, 2026, 3:16 AM EDT
Terminated Not applicable Interventional Results available

Evaluation of the Technical Success of IVUS Guided VCF Placement Using the LUMIFI™ With Crux® VCF System

NCT02394912
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis
Interventions
vena cava filter implantation (LUMIFI with Crux VCF System)
Device
Lead sponsor
Volcano Corporation
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Louisville, Kentucky • Orangeburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 4, 2026, 3:16 AM EDT
Completed Not applicable Interventional Results available

Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival

NCT01640171
View directory record Official record
Conditions
Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel, Acuvail, Intra-vitreal Anti-VEGF Drug
Procedure · Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 4, 2026, 3:16 AM EDT
Completed Phase 2 Interventional

An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study

NCT00402467
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban, (BAY59-7939), Enoxaparine
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 4, 2026, 3:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility Study of Exercise in Patients With Leg Blood Clots

NCT00910364
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Exercise
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
21 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 4, 2026, 3:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bedside Ultrasound in the Assessment of Deep Venous Thrombosis: Effectiveness of In-Person Versus Online Instruction

NCT03573492
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Education
Other
Lead sponsor
Mercy Health Ohio
Other
Eligibility
Not listed
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 4, 2026, 3:16 AM EDT
Completed No phase listed Observational

Coagulation Changes in Trauma Patients

NCT00795743
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 4, 2026, 3:16 AM EDT
Terminated Phase 3 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

NCT03203447
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
suprachoroidal CLS-TA, suprachoroidal sham, Lucentis or Avastin
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 4, 2026, 3:16 AM EDT
Terminated Phase 3 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

NCT02980874
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
suprachoroidal CLS-TA, suprachoroidal sham, IVT aflibercept
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
58
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 4, 2026, 3:16 AM EDT
Not listed Not applicable Interventional

SToP: Venous Thromboembolism Screening in the Trauma Population

NCT02978950
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis, Trauma, Multiple
Interventions
Duplex ultrasound surveillance, No ultrasound surveillance
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 4, 2026, 3:16 AM EDT
Completed Phase 2Phase 3 Interventional Results available

The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients

NCT00531843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
fondaparinux sodium, sequential compression devices
Drug · Device
Lead sponsor
Mary Knudson, M.D.
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 4, 2026, 3:16 AM EDT
Completed Phase 3 Interventional Results available

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

NCT02798471
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
Interventions
Edoxaban, Standard of Care
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Day to 17 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 4, 2026, 3:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patient Safety Learning Laboratory: Making Acute Care More Patient-Centered

NCT02969343
View directory record Official record
Conditions
Central Line-Associated Bloodstream Infection (CLABSI), Venous Thromboembolism, Patient Fall, Catheter-Associated Infection, Severe Hypoglycemia, Opioid-Related Severe Adverse Drug Event, Hospital Acquired Pressure Ulcer, Adverse Drug Event, Severe Hospital Acquired Delerium, Rapid Response Related to Arrhythmia
Interventions
Patient Safety health information technology
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
21,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 4, 2026, 3:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years

NCT06562985
View directory record Official record
Conditions
Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
Interventions
BAY3018250 Dose 1, Placebo, BAY3018250 Dose 2 infusion, BAY3018250 Dose 2 injection
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 4, 2026, 3:16 AM EDT
Terminated No phase listed Observational

Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin

NCT05819125
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
21,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 4, 2026, 3:16 AM EDT